Adaptive Biotechnologies (ADPT) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Less: Income from discontinued operations, net of taxes	0
Income (loss) from continuing operations, net of taxes
Stock-based compensation expense	3.16M
Inventory-related charges
Depreciation and amortization	23.61M
Gain on release of foreign currency translation, net of taxes
Adjustment of deferred taxes	-6.55M
Loss on retirement/impairment of assets
Changes in current assets and liabilities
Net cash provided by (used in) operating activities of continuing operations
Net cash provided by operating activities of discontinued operations	0
Net cash provided by (used in) operating activities	26.52M
Purchases of intangible assets
Purchases of property and equipment	-4.79M
Purchases of marketable securities	-43.43M
Sales of marketable securities	43.34M
Maturities of marketable securities	0
Net cash used in investing activities of continuing operations
Net cash provided by investing activities of discontinued operations
Net cash used in investing activities	-5.18M
Repurchases of long-term debt	-36.34M
Proceeds from issuance of common stock
Net cash provided by financing activities of continuing operations
Net cash provided by financing activities	-41.54M
Effect of foreign currency translation on cash and cash equivalents	-8K
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period	51.91M
Cash and cash equivalents, end of period	31.71M
Unrealized gains (losses) on available-for-sale securities, net of taxes

Entities mentioned with ADPT

View All Entities